CTIS2023-508703-21-00招募中1 期
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers - MK-9999-02A
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 139
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.Has one of the following cancers: •Unresectable or metastatic colorectal cancer •Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) •Advanced and/or unresectable biliary tract cancer (BTC), 2.Has received one previous treatment for the cancer (colorectal cancer, PDAC); has received one or two previous treatments for BTC, 3.Has recovered from any side effects due to previous cancer treatment
排除标准
- •1.History of severe eye disease, 2.Received prior treatment with a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC)., 3.Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention.
研究者
相似试验
进行中（未招募）
1 期
A trial to understand if AZD0486 is safe and helps in people with Relapsed or Refractory B-cell acute lymphoblastic leukemia (B-ALL)CTIS2023-505840-20-00Astrazeneca AB153
招募中
1 期
AGN-193408 SR in the treatment of open-angle glaucoma or ocular hypertensioOcular hypertensionOpen-angle glaucomaJPRN-jRCT2031220053Yamazaki Hayato84
进行中（未招募）
1 期
Study conducted to learn more about the safety and effects of CTX001 (the Study Therapy”) in patients with Severe Sickle Cell DiseaseMedDRA version: 20.0Level: PTClassification code 10043391Term: Thalassaemia betaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersSickle Cell DiseaseEUCTR2018-001320-19-ITVERTEX PHARMACEUTICALS INCORPORATED45
进行中（未招募）
1 期
A study to learn about the safety and efficacy of CTX001 (the study drug product) to treat Severe Sickle Cell DiseaseSevere Sickle Cell Disease (SCD)MedDRA version: 21.0Level: PTClassification code 10040641Term: Sickle cell anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-001320-19-GBVertex Pharmaceuticals Incorporated45
进行中（未招募）
1 期
An early study to test IMGN901 with carboplatin and etoposide for treating adult patients with certain types of cancer including small cell lung cancerPhase 2: small cell lung cancer (extensive-stage disease)MedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10041058 Term: Small cell carcinoma of the lung System Organ Class: 100000004864EUCTR2010-022950-17-GBImmunoGen, Inc181